CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$49.49 USD
-0.10 (-0.20%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $49.51 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 181 - 200 ( 225 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Scientific Presentations Highlight Various Allogeneic CAR Constructs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
New Trial Posted Last Night on Clinicaltrials.gov for Solid Tumor Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Updated Model with $105 PT on the Heels of EHA Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Cuts Away Troubling Inherited Hemoglobin Diseases
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
EHA Presentation on a Third Beta-thal Patient Treated with Crispr-Cas9. And There Is AACR.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
See Our Highlights from AACR II (June 22-24, 2020) Meeting Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
1Q20: Four Programs in the Clinic. IND Approved for the Fifth
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department